Aigen Investment Management LP Has $1.26 Million Stake in Zoetis Inc. (NYSE:ZTS)

Aigen Investment Management LP trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 22.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,720 shares of the company's stock after selling 2,186 shares during the quarter. Aigen Investment Management LP's holdings in Zoetis were worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. Darwin Wealth Management LLC bought a new position in Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in Zoetis in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the 3rd quarter worth approximately $33,000. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE:ZTS traded up $3.09 on Friday, reaching $170.34. 3,296,788 shares of the company traded hands, compared to its average volume of 3,274,650. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The company's 50 day moving average is $166.72 and its 200-day moving average is $176.78. The stock has a market capitalization of $76.28 billion, a PE ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Remove Ads

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis's dividend payout ratio is 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ZTS has been the subject of a number of recent analyst reports. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target for the company. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Zoetis currently has an average rating of "Buy" and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.